Get the Stockscreener App
126.59
1.03%
-1.32
After Hours:
126.59
Neurocrine Biosciences Inc stock is traded at $126.59, with a volume of 725.71K.
It is down -1.03% in the last 24 hours and up +9.05% over the past month.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
See More
Previous Close:
$127.91
Open:
$127.91
24h Volume:
725.71K
Relative Volume:
0.71
Market Cap:
$12.69B
Revenue:
$2.24B
Net Income/Loss:
$385.90M
P/E Ratio:
68.06
EPS:
1.86
Net Cash Flow:
$440.10M
1W Performance:
+2.68%
1M Performance:
+9.05%
6M Performance:
-9.19%
1Y Performance:
+12.01%
1-Day Range:
$125.43
$128.27
1-Week Range:
$122.37
$128.27
52-Week Range:
$110.81
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
126.59 | 12.69B | 2.24B | 385.90M | 440.10M | 1.86 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Dai ichi Life Insurance Company Ltd Sells 6,358 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Qsemble Capital Management LP Makes New $1.24 Million Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Holdings Decreased by Loomis Sayles & Co. L P - MarketBeat
Thrivent Financial for Lutherans Has $2.97 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Endometriosis Market expected to rise | Companies – AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, expected to drive mar - Barchart
Neurocrine Biosciences to Present at Evercore and Citi Healthcare Conferences in December | NBIX Stock News - StockTitan
Connor Clark & Lunn Investment Management Ltd. Has $1.98 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Cerebral Palsy Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Neurocrine Biosciences, Teva Pharma, Bundang CHA Hospital, Jazz Pharma - Barchart
Cerebral Palsy Market to Show Remarkable Growth Trends from 2024 - openPR
Massachusetts Financial Services Co. MA Increases Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Invests $553,000 in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
When (NBIX) Moves Investors should Listen - Stock Traders Daily
Natixis Advisors LLC Has $3.38 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Landscape Capital Management L.L.C. Takes $1 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Advisors Asset Management Inc. Purchases 4,549 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Eagle Asset Management Inc. Sells 58,671 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Eagle Asset Management Inc. Has $78.13 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Primecap Management Co. CA Lowers Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Intech Investment Management LLC Raises Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Jennison Associates LLC Has $38.58 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Buys 37,098 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Swiss National Bank Boosts Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Tardive Dyskinesia Treatment Market Expected to Reach High - openPR
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by KBC Group NV - MarketBeat
Victory Capital Management Inc. Increases Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Empowered Funds LLC - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Impax Asset Management Group plc - MarketBeat
GSA Capital Partners LLP Purchases 7,078 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Position Boosted by Plato Investment Management Ltd - MarketBeat
Aigen Investment Management LP Acquires New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
(NBIX) Trading Report - Stock Traders Daily
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus - Yahoo Finance
Strategic Sale: EIRY ROBERTS Decides To Exercise Options Worth $334K At Neurocrine Biosciences - Benzinga
Principal Financial Group Inc. Sells 120,576 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio - Benzinga
Neurocrine Biosciences: Healthcare Marketing Impact Awards 2024 - Modern Healthcare
Why AbbVie’s disappointing schizophrenia drug trial bodes well for Bristol Myers - MarketWatch
How Neurocrine Biosciences helps health care professionals diagnose a movement disorder - Ad Age
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned - BioPharma Dive
Neurocrine Biosciences (NASDAQ:NBIX) Earns "Hold" Rating from Needham & Company LLC - MarketBeat
Los Angeles Capital Management LLC Increases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Fiera Capital Corp Decreases Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels (NASDAQ:NBIX) - Seeking Alpha
Summit Global Investments Sells 24,024 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences' (NASDAQ:NBIX) Strong Earnings Are Of Good Quality - Yahoo Finance Australia
Beacon Harbor Wealth Advisors Inc. Buys Shares of 47,917 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Kornitzer Capital Management Inc. KS Makes New $3.59 Million Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences presents new KINECT®-HD data showing consistent efficacy across 19 subgroups and improvements in aspects of emotional health with Ingrezza (valbenazine) capsules - PharmaLive
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules - PR Newswire
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):